BDTX
Black Diamond Therapeutics, Inc. NASDAQ Listed Jan 31, 2020$1.71
+0.59%
vs $1.70
Mkt Cap $98.4M
52w Low $1.61
3.1% of range
52w High $4.87
50d MA $2.45
200d MA $2.85
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.1x
ROE
19.9%
P/FCF
3.3x
RSI (14)
35.20
ATR (14)
$0.14
Beta
3.39
50d MA
$2.45
200d MA
$2.85
Avg Volume
2.4M
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
One Main Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.18 | -0.14 | +22.2% | 2.19 | -3.7% | +1.8% | -2.7% | -0.9% | -1.9% | +1.9% | — |
| Nov 6, 2025 | AMC | -0.22 | -0.15 | +31.8% | 3.98 | -1.3% | -2.3% | +12.1% | +6.0% | +5.4% | -7.8% | — |
| Aug 7, 2025 | AMC | -0.25 | -0.19 | +24.0% | 2.28 | +0.0% | +5.3% | -3.8% | +10.0% | +9.1% | +0.7% | — |
| May 12, 2025 | AMC | 0.02 | 0.98 | +4800.0% | 1.75 | +10.9% | +10.3% | -2.1% | +2.1% | +1.0% | +8.2% | — |
| Mar 6, 2025 | AMC | -0.31 | -0.28 | +9.7% | 1.90 | -3.2% | -1.1% | -9.0% | -1.2% | +5.9% | -7.8% | — |
| Nov 5, 2024 | AMC | -0.37 | -0.28 | +24.3% | 3.25 | +0.9% | +1.2% | -3.3% | +3.5% | +2.7% | -4.1% | — |
| Aug 6, 2024 | AMC | -0.39 | -0.36 | +7.7% | 5.01 | -0.2% | -9.0% | +6.4% | -4.3% | +0.9% | +14.5% | — |
| May 9, 2024 | AMC | -0.44 | -0.35 | +20.5% | 6.75 | -2.2% | -9.5% | -2.8% | -3.4% | -5.2% | -3.7% | — |
| Mar 12, 2024 | AMC | -0.47 | -0.34 | +27.7% | 3.78 | +1.3% | +10.8% | +8.4% | +5.5% | -1.9% | -1.5% | — |
| Nov 6, 2023 | AMC | -0.49 | -0.45 | +8.2% | 1.91 | +0.0% | -4.7% | +1.6% | -2.7% | -1.1% | +6.7% | — |
| Aug 11, 2023 | AMC | -0.54 | -0.52 | +3.7% | 3.33 | +2.7% | -1.2% | -3.6% | -2.8% | +0.0% | +2.6% | — |
| May 9, 2023 | AMC | -0.61 | -0.57 | +6.6% | 1.82 | +0.5% | +3.3% | +2.1% | -1.6% | +2.1% | -5.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $2.70 | $2.74 | +1.5% | -4.8% | +3.1% | -1.9% | +3.8% | +6.3% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $2.19 | $2.11 | -3.7% | +1.8% | -2.7% | -0.9% | -1.9% | +1.9% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.67 | $2.66 | -0.4% | -4.1% | -6.2% | +7.1% | +3.1% | -1.5% |
| Dec 4 | Guggenheim | Downgrade | Buy → Neutral | — | $2.69 | $2.70 | +0.4% | +0.7% | -1.5% | +3.0% | -1.5% | -1.5% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.43 | +1.2% | -3.8% | +10.0% | +9.1% | +0.7% | -1.1% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.73 | +1.2% | -1.8% | +2.4% | +9.3% | -5.3% | -5.6% |
| Mar 7 | Stifel | Maintains | Buy → Buy | — | $1.90 | $1.84 | -3.2% | -1.1% | -9.0% | -1.2% | +5.9% | -7.8% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.25 | $3.28 | +0.9% | +1.2% | -3.3% | +3.5% | +2.7% | -4.1% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.54 | -0.6% | -0.3% | -3.1% | -3.2% | +4.5% | -2.3% |
| Oct 8 | Wedbush | Maintains | Outperform → Outperform | — | $3.66 | $3.61 | -1.4% | -2.7% | -0.3% | -3.1% | -3.2% | +4.5% |
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.50 | +0.0% | +1.8% | -8.3% | +5.0% | -4.1% | +2.8% |
| Sep 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.76 | $5.64 | +18.5% | -5.5% | +1.8% | -8.3% | +5.0% | -4.1% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.88 | +1.0% | -2.1% | +1.1% | -0.4% | -5.5% | +1.8% |
| Sep 10 | Wedbush | Maintains | Outperform → Outperform | — | $5.66 | $5.66 | +0.0% | +7.1% | +1.2% | -4.6% | +5.8% | -12.4% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.77 | $5.70 | -1.2% | -2.6% | -0.7% | -3.2% | +4.8% | +7.1% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $5.01 | $5.00 | -0.2% | -9.0% | +6.4% | -4.3% | +0.9% | +14.5% |
| Jul 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.21 | $4.23 | +0.5% | +5.5% | +0.7% | -2.2% | +14.6% | +2.4% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.61 | -0.9% | +11.6% | -1.5% | +19.4% | +2.3% | -1.1% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.44 | +0.0% | -3.7% | -7.1% | +0.6% | +1.4% | +1.4% |
| Apr 8 | Wedbush | Maintains | Outperform → Outperform | — | $5.06 | $5.24 | +3.6% | +5.7% | +0.2% | -7.1% | +11.8% | -5.9% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.92 | +2.7% | -1.9% | -1.5% | +0.4% | +16.3% | +6.1% |
| Mar 13 | Wedbush | Maintains | Outperform → Outperform | — | $3.78 | $3.83 | +1.3% | +10.8% | +8.4% | +5.5% | -1.9% | -1.5% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.25 | +0.9% | +4.9% | -3.4% | -0.9% | -0.4% | -2.7% |
| Sep 12 | Wedbush | Maintains | Outperform → Outperform | — | $3.48 | $3.47 | -0.3% | +2.0% | +0.8% | +0.6% | -1.4% | -1.4% |
| Jun 30 | Stifel | Upgrade | Hold → Buy | — | $5.03 | $5.32 | +5.8% | +0.4% | -7.1% | +3.6% | -7.8% | -1.6% |
| Jun 28 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $6.18 | $5.85 | -5.3% | -7.3% | -12.2% | +0.4% | -7.1% | +3.6% |
| Jun 27 | Stifel | Maintains | Hold → Hold | — | $1.84 | $4.17 | +126.6% | +235.9% | -7.3% | -12.2% | +0.4% | -7.1% |
| Jun 27 | Wedbush | Upgrade | Neutral → Outperform | — | $1.84 | $4.17 | +126.6% | +235.9% | -7.3% | -12.2% | +0.4% | -7.1% |
| May 10 | Wedbush | Maintains | Neutral → Neutral | — | $1.82 | $1.83 | +0.5% | +3.3% | +2.1% | -1.6% | +2.1% | -5.7% |
| Mar 29 | Wedbush | Downgrade | Outperform → Neutral | — | $2.76 | $2.75 | -0.4% | +1.8% | -1.4% | +0.0% | -0.7% | +1.1% |
| Mar 22 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.11 | $3.00 | -3.5% | +1.6% | -0.3% | -1.3% | -10.3% | -1.1% |
| Mar 18 | Stifel | Maintains | Hold → Hold | — | $3.02 | $3.07 | +1.7% | +5.0% | -1.9% | +1.6% | -0.3% | -1.3% |
| Sep 30 | Stifel | Maintains | Hold → Hold | — | $9.06 | $9.05 | -0.1% | -6.6% | +0.2% | -5.0% | -2.1% | -2.5% |
| Jan 7 | Wedbush | Maintains | Outperform → Outperform | — | $33.23 | $34.08 | +2.6% | +2.3% | +0.3% | +1.9% | -14.8% | +0.5% |
| Nov 24 | Berenberg | Maintains | Buy → Buy | — | $33.54 | $34.92 | +4.1% | +1.3% | -1.6% | +2.9% | -3.1% | -3.3% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.49 | $33.79 | -2.0% | +7.9% | +1.8% | +1.5% | +4.5% | +5.0% |
| Feb 24 | TD Cowen | Maintains | Outperform → Outperform | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | JP Morgan | Maintains | Overweight → Overweight | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
| Feb 24 | Jefferies | Maintains | Buy → Buy | — | $37.92 | $37.00 | -2.4% | -12.3% | -1.7% | -2.2% | -9.7% | -6.6% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Acadian Asset Management Llc | 2,348,651 | $5M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,850,468 | $4M | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 1,643,747 | $4M | Added | Mar 2026 |
| 4 | Jane Street Group, Llc | 961,776 | $2M | Added | Dec 2025 |
| 5 | Marshall Wace, Llp | 836,266 | $2M | Reduced | Mar 2026 |
| 6 | Arrowstreet Capital, Limited Partnership | 834,570 | $2M | Reduced | Mar 2026 |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 654,699 | $2M | Added | Dec 2025 |
| 8 | Fmr Llc | 623,827 | $1M | Added | Mar 2026 |
| 9 | Ubs Group Ag | 564,838 | $1M | Added | Mar 2026 |
| 10 | Man Group Plc | 559,700 | $1M | Added | Mar 2026 |
| 11 | Winton Group Ltd | 538,259 | $1M | Added | Mar 2026 |
| 12 | Citadel Advisors Llc | 502,652 | $1M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 464,708 | $990K | Reduced | Mar 2026 |
| 14 | D.e. Shaw & Co | 363,921 | $775K | Reduced | Mar 2026 |
| 15 | Vanguard Fiduciary Trust Co | 259,908 | $554K | New | Mar 2026 |
| 16 | Morgan Stanley | 190,298 | $462K | Added | Dec 2025 |
| 17 | Bank Of New York Mellon Corp | 189,148 | $403K | Reduced | Mar 2026 |
| 18 | Round Rock Advisors Llc | 124,564 | $303K | New | Dec 2025 |
| 19 | Millennium Management | 134,979 | $288K | Reduced | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 114,143 | $243K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$98.4M
Enterprise Value
-$30.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.05x
P/B
0.87x
P/S
—
P/FCF
3.32x
EV/EBITDA
—
Shares Out
57.6M
Financials (TTM)
Revenue
$0
Net Income
-$43.2M
EBITDA
-$38.1M
Free Cash Flow
$29.6M
Op Cash Flow
$29.6M
EPS Basic
$0.39
EPS Diluted
$-0.76
EPS Forward
$-0.64
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$143.0M
Total Liab.
$30.8M
Total Equity
$112.2M
Cash
$128.7M
LT Debt
$0
Book Value/Sh
$1.97
Debt/Equity
0.13x
Current Ratio
8.42
Quick Ratio
8.42
Returns & Growth
ROE
19.9%
ROA
15.6%
ROIC
15.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
+130.7%
Price Returns
2W
-22.4%
1M
-16.2%
3M
-10.1%
6M
-41.9%
12M
+0.9%
Technicals
52W High
$4.87
52W Low
$1.61
50d MA
$2.45
200d MA
$2.85
RSI (14)
35.20
ATR (14)
$0.14
Beta
3.39
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.00
High
$8.00
Low
$8.00
Median
$8.00
Data updated apr 24, 2026 9:03pm
· Source: financialmodelingprep.com